Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

NCT02445612 is registered in ClinicalTrials.gov with Astellas Institute for Regenerative Medicine as lead sponsor.

NCT NCT02445612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02445612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
Lead sponsor
Astellas Institute for Regenerative Medicine
Phase
Observational
Overall status
Completed
Start date
July 11, 2012
Completion date
June 21, 2019
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

stargardt's macular dystrophy